Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brant Victor

Physician Assistant, Surgical Austin, TX Physician Assistant

NPI 1871982645 CMS profile 10884464

1301 W 38Th St, Ste 200, Austin, TX 78705

Open in the dashboard

General payments

$5,078

66 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brant Victor of Austin, TX is reported in the CMS Open Payments database as having received $5,078 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,706 15
2024 General $344 10
2023 General $2,499 21
2022 General $482 17
2021 General $46 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brant Victor
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Brant Victor were reported at $1,706. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Brant Victor Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $46 $111 $36–$285 $132
2022 $482 $126 $44–$350 $149
2023 $2,499 $137 $47–$355 $160
2024 $344 $146 $49–$384 $164
2025 $1,706 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Smith+Nephew, Inc. $3,849 18 payments
  2. Stryker Corporation $1,032 39 payments
  3. Pacira Pharmaceuticals Incorporated $51 2 payments
  4. Bioventus LLC $50 2 payments
  5. Davol Inc. $41 2 payments
  6. Medinc of Texas $21 1 payment
  7. DePuy Synthes Sales Inc. $20 1 payment
  8. KCI USA, Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $2,687 6 payments
  2. Food and Beverage $2,391 60 payments
Products named General payments · program years 2021–2025
  1. JOURNEY $3,071 9 payments
  2. RI Hip Navigation $3,071 9 payments
  3. OR3O Dual Mobility $2,012 6 payments
  4. POLARSTEM $1,749 7 payments
  5. REAL INTELLIGENCE $1,517 7 payments
  6. JOURNEY II Recon Knees $1,059 3 payments
  7. TANDEM $798 2 payments
  8. MAKO $763 27 payments
  9. JOURNEY II Recon Knees $150 1 payment
  10. DALL-MILES $70 3 payments
  11. Other $314 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

392

Median for Physician Assistant: 241

Drug cost

$3,098

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 74 $1,675
Gabapentin Generic 39 $327
Meloxicam Generic 97 $234
Diclofenac Sodium Generic 17 $189
Methylprednisolone Generic 16 $166
Tramadol Hcl Generic 45 $158
Doxycycline Hyclate Generic 14 $154
Cephalexin Generic 13 $81
Methocarbamol Generic 15 $53
Amoxicillin Generic 42 $47

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$157,024

Of which drugs: $94,140

Medicare patients

369

Average age 75

Services billed

23,827

241 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Ischemic heart disease 37%
Depression 24%
Diabetes 20%
Cancer 19%
Osteoporosis 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 17 86 $8,342
Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 Office 31 15,496 $6,211
Injection, methylprednisolone acetate, 1 mg J1010 Office 70 6,325 $638
Injection, methylprednisolone acetate, 80 mg J1040 Office 30 33 $169

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record